EUVIMEDEUVIMED entdecken
Crossref

CD161⁺ Treg as a potential biomarker for evaluating disease activity and treatment efficacy in rheumatoid arthritis

Ziyi Song, Danxue Zhu, Feng Sun, Jiayi Geng, Chuanhui Xu, Junyi Jiang, Wenjuan Zhang, Xiaolin Sun, Zhanguo Li

Clinical Rheumatology · 2026

DOI: 10.1007/s10067-026-08056-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Ziyi Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, NK Cell Lectin-Like Receptor Subfamily B, Arthritis, Rheumatoid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: CD161⁺ regulatory T cells (Tregs) are involved in rheumatoid arthritis (RA) pathogenesis. This study aimed to investigate the levels of circulating CD161⁺ Tregs in RA patients and to evaluate their associations with clinical features, laboratory indicators, and therapeutic responses. METHODS: A total of 172 RA patients meeting the 2010 ACR/EULAR criteria and 110 age- and sex-matched healthy controls (HCs) were enrolled. The proportion of CD161⁺ Tregs in peripheral blood was quantified by flow cytometry. Correlations between CD161⁺ Treg levels and clinical manifestations, laboratory parameters, and disease activity scores (DAS28) were assessed. Twenty-four RA patients were longitudinally followed to assess post-treatment changes in CD161⁺ Tregs and disease activity. RESULTS: The proportions of CD161⁺ Tregs of the total Treg and CD4⁺ T cell populations were significantly elevated in RA patients compared to HCs (P 5.1) compared to those with moderate/low disease activity (P < 0.05). After treatment, decreased CD161⁺ Treg and disease activity scores were observed (P < 0.05), which were particularly pronounced in the group receiving csDMARDs combined with tocilizumab (an IL-6 inhibitor). However, csDMARDs alone or in combination with JAK inhibitors showed no or only partial efficacy. CONCLUSION: CD161⁺ Tregs are elevated in RA and associated with disease activity and immunologic indicators. CD161⁺ Tregs might serve as a biomarker for assessing RA disease activity. Key Points • The proportion of circulating CD161⁺ regulatory T cells is significantly increased in rheumatoid arthritis patients compared to healthy controls. • Higher CD161⁺ Treg levels correlate positively with disease activity scores (DAS28-ESR) and key serological markers (RF, IgA, IgM). • CD161⁺ Treg levels decreased significantly following effective therapy, paralleling reductions in disease activity, particularly in the group receiving csDMARDs combined with tocilizumab. • CD161⁺ Tregs show positive correlations with pro-inflammatory cells (TNF-α+CD4+T cell, Th17) and peripheral T follicular helper cells, underscoring their role in RA immunopathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryNK Cell Lectin-Like Receptor Subfamily BArthritis, RheumatoidBiomarkersCase-Control StudiesLongitudinal StudiesDisease ProgressionAntirheumatic AgentsTreatment OutcomeSeverity of Illness IndexHumansMaleFemaleAdultMiddle AgedAgedFlow Cytometry

Stichwörter der Autor:innen

BiomarkerCD161⁺ TregsDisease activityRheumatoid arthritisTherapeutic response

Substanzen

BiomarkersKLRB1 protein, humanNK Cell Lectin-Like Receptor Subfamily BAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.
  • Beijing Key Laboratory of Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Beijing, 100044, China.
  • Department of Thoracic Surgery, Peking University People's Hospital, Beijing, 100044, China.
  • Thoracic Oncology Institute & Research Unit of Intelligence Diagnosis and Treatment in Early Non-Small Cell Lung Cancer, Peking University People's Hospital, Beijing, China.
  • Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Jln Tan Tock Seng, Singapore, 308433, Singapore.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Song, Z., Zhu, D., Sun, F., Geng, J., Xu, C., Jiang, J., Zhang, W., Sun, X., & Li, Z. (2026). CD161⁺ Treg as a potential biomarker for evaluating disease activity and treatment efficacy in rheumatoid arthritis. Clinical Rheumatology. https://doi.org/10.1007/s10067-026-08056-4

Vancouver

Song Z, Zhu D, Sun F, Geng J, Xu C, Jiang J, et al. CD161⁺ Treg as a potential biomarker for evaluating disease activity and treatment efficacy in rheumatoid arthritis. Clinical Rheumatology. 2026. doi:10.1007/s10067-026-08056-4

BibTeX
@article{Song2026,
  author = {Song, Ziyi and Zhu, Danxue and Sun, Feng and Geng, Jiayi and Xu, Chuanhui and Jiang, Junyi and Zhang, Wenjuan and Sun, Xiaolin and Li, Zhanguo},
  title = {CD161⁺ Treg as a potential biomarker for evaluating disease activity and treatment efficacy in rheumatoid arthritis},
  journal = {Clinical Rheumatology},
  year = {2026},
  doi = {10.1007/s10067-026-08056-4}
}
Kostenlos starten →